RAMM Pharma

RAMM Pharma Stock-Based Compensation

Stock-Based Compensation (SBC) of RAMM Pharma (RAMM.CN) as of Oct 29, 2026.

Stock-Based Compensation

0.00CAD

Last updated:

Stock-Based Compensation (SBC) of RAMM Pharma is 2025 0.00 CAD. Stock-Based Compensation (SBC) of RAMM Pharma was 2024 169,634.00 CAD. It decreases by % lower compared to the previous year.

The RAMM Pharma Stock-Based Compensation history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Stock-Based Compensation
Date
Stock-Based Compensation
Jan 1, 2019
37,405.00 CAD
Jan 1, 2020
4.75 M CAD
Jan 1, 2021
699,186.00 CAD
Jan 1, 2022
383,677.00 CAD
Jan 1, 2023
14,198.00 CAD
Jan 1, 2024
169,634.00 CAD
Jan 1, 2025
0.00 CAD
The RAMM Pharma Stock-Based Compensation history
YEARStock-Based CompensationYoY
0.00CAD-100.00%
169,634.00CAD+1,094.77%
14,198.00CAD-96.30%
383,677.00CAD-45.13%
699,186.00CAD-85.28%
4.75 MCAD+12,596.52%
37,405.00CAD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

RAMM Pharma Stock analysis

What does RAMM Pharma do? RAMM Pharma Corp generates revenue through cannabinoid pharmaceuticals and cannabis-based products, with brands like NettaLife, NettaPet, NettaPet Senior, NettaPet Puppies, and NettaVet targeting pet owners and veterinary markets. The company also sells cosmetics under the Cannabipiel line, including Cannabipiel Nite, Cannabipiel Body Lotion, and Cannabipiel Shampoo, catering to consumers seeking cannabinoid-infused skincare and personal care solutions. Subsidiaries such as Canapar Corp. and Medic Plast SA support production and commercialization across pharmaceutical specialties, household products, and food sectors. The firm’s product portfolio spans pharmaceuticals, pet care, cosmetics, and household items, with NettaPet and NettaVet focusing on animal health and Cannabipiel products targeting human skincare. Revenue streams include direct sales of branded items like Cannabipiel Tite and Cannabipiel Cleaning Emulsion to retail and specialty markets, while subsidiaries handle manufacturing and export operations for global distribution. Brands like Glediser SA and Yurelan SA contribute to the commercialization of diverse product categories under the company’s umbrella. RAMM Pharma is one of the most popular companies on Eulerpool.

Frequently Asked Questions about RAMM Pharma stock

On Eulerpool you can find the complete historical development of Stock-Based Compensation (SBC) RAMM Pharma since 2006 – with annual values, charts, and detailed analysis.

Stock-based compensation is a non-cash expense representing equity awards to employees. High SBC can dilute existing shareholders and inflate reported cash flow.

Stock-Based Compensation (SBC)'s CAD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Stock-Based Compensation (SBC)'s RAMM Pharma historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cash Flow — RAMM Pharma

All Key Metrics — RAMM Pharma